Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation  by Fedak, Paul W.M. et al.
Cardiothoracic
TransplantationCombined endothelial and myocardial protection by
endothelin antagonism enhances transplant allograft
preservation
Paul W. M. Fedak, MD, PhD
Vivek Rao, MD, PhD
Subodh Verma, MD, PhD
Danny Ramzy, MD
Laura Tumiati, BSc
Santiago Miriuka, MD
Patty Boylen
Richard D. Weisel, MD
Christopher M. Feindel, MD
TXFrom Toronto General Hospital, University
Health Network, Division of Cardiac Sur-
gery, University of Toronto, Toronto, On-
tario, Canada.
Supported by the Heart and Stroke Foun-
dation of Canada (Grant T4732), the Cana-
dian Institutes for Health Research, The
Thoracic Surgery Foundation for Research
and Education, and The American Associ-
ation for Thoracic Surgery. P.W.M.F. is a
Research Fellow of the HSFC. D.R. is a
Research Fellow of the TSFRE. V.R. is a
CIHR New Investigator and a recipient of
the second Robert E. Gross Research
Scholarship from the AATS.
Read at the Eighty-fourth Annual Meeting
of The American Association for Thoracic
Surgery, Toronto, Ontario, Canada, April
25-28, 2004.
Received for publication May 4, 2004; re-
visions received Aug 24 2004; accepted for
publication Sept 2, 2004.
Address for reprints: Vivek Rao, MD, PhD,
FRCS, EN14-222, Toronto General Hospital,
200 Elizabeth St, Toronto, Ontario, M5G
2C4, Canada (E-mail: vivek.rao@uhn.
on.ca).
J Thorac Cardiovasc Surg 2005;129:407-15
0022-5223/$30.00
Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.09.031Background: Endothelin is a potent inflammatory peptide associated with myocar-
dial dysfunction, coronary vasculopathy, and reduced survival after cardiac trans-
plantation. We hypothesized that endothelin antagonism during cardiac allograft
storage would limit early endothelial dysfunction and improve myocardial perfor-
mance after transplantation.
Methods: Porcine orthotopic transplantations (n 16) were performed after 6 hours
of ischemic storage. Intermittent donor blood perfusion (control, n  8) was
compared with donor blood perfusion enhanced with 100 mol/L of an endothelin
receptor blocker (n  8). Left ventricular performance was assessed after caval
occlusion with a Millar micromanometer and conductance catheter. Coronary en-
dothelial function was assessed in vitro with a macrovascular tissue bath apparatus.
Myocardial endothelin, tumor necrosis factor , and transforming growth factor 
protein expression were determined. Oxidative stress was inferred on the basis of
8-isoprostane levels, and myocardial metabolism was inferred on the basis of the
extraction or production of oxygen, acid, and lactate by the heart.
Results: Endothelial function was diminished 48 hours after transplantation but not
earlier. Endothelin receptor blocker treatment during preservation limited coronary
endothelial dysfunction 48 hours after reperfusion (P  .001). Weaning from
cardiopulmonary bypass and left ventricular performance after transplantation was
improved in endothelin receptor blocker–treated hearts (P  .02). Myocardial
endothelin expression was equivalent in both groups and increased during reperfu-
sion after transplantation (P  .001). Tumor necrosis factor  levels decreased with
endothelin receptor blocker treatment (P  .02), whereas transforming growth
factor  levels did not change (P  .86). 8-Isoprostane, oxygen, acid, and lactate
levels were similar, suggesting that oxidative stress and metabolism were not
important mechanisms of benefit.
Conclusions: Endothelin accumulates during allograft storage and contributes to
endothelial and myocardial dysfunction after transplantation. Endothelin blockade
during allograft preservation limits endothelial injury and enhances ventricular
recovery after transplantation.
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TXMyocardial protection for routine car-diac surgery has improved with time,but surprisingly, cardiac allograftpreservation for transplantation hasnot evolved similarly. With conven-tional cold storage techniques, the
safe duration of allograft storage is restricted, and prolonged
storage times (6 hours) continue to be associated with
compromised short- and long-term outcomes. Specifically,
myocardial injury caused by prolonged storage compro-
mises contractile performance, resulting in low output syn-
drome and sometimes death. In addition, endothelial injury
as a result of prolonged storage is increasingly recognized
as an important cause of poor outcome after cardiac trans-
plantation,1 principally because it might lead to transplant
vasculopathy,2,3 a leading cause of late mortality in trans-
plant recipients. Improved methods of cardiac allograft pro-
tection will enhance the recovery of grafts subjected to
prolonged ischemia and facilitate the retrieval of distant
donor hearts. Allograft preservation might be optimized if
both the myocardium and endothelium are simultaneously
targeted and protected during storage.
Endothelin (ET-1) is a potent inflammatory peptide with
profound biologic effects on both endothelium and myocar-
dium. ET-1 accumulates in the heart during the ischemia and
reperfusion associated with cardiac surgery.4 In coronary ar-
tery bypass graft surgery, increased perioperative ET-1 signal-
ing is associated with poor postoperative clinical outcomes.5 In
patients undergoing cardiac transplantation, heightened ET-1
bioactivity is associated with early myocardial dysfunction,
late coronary vasculopathy, and reduced overall survival.3,4,6-8
We developed a preservation method by using limited
coronary perfusion provided by donor blood harvested at
the time of organ procurement that can improve both met-
abolic and functional recovery after transplantation com-
pared with conventional storage techniques.9 Our perfusion
technique is simple, straightforward, and clinically applica-
ble. In addition, our perfusion approach provides an oppor-
tunity to add pharmacologic supplements to the perfusate
and by this means identify novel agents to enhance recov-
ery. We hypothesized that adding an ET-1 antagonist in the
blood perfusate during cardiac allograft storage would pro-
vide dual endothelial and myocardial protection and, in so
doing, limit early endothelial dysfunction and improve
myocardial performance after transplantation.
Methods
All experimental protocols were approved by our institutional
animal care committee, and animals were cared for in accordance
with the guidelines of the Canadian Council for Animal Care.
Donor Procedure
Female Yorkshire pigs (approximately 70 kg) were used for both
donor and recipient, and the donor heart was harvested as previ-
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placed around the superior and inferior venae cavae to permit
adjustment of cardiac preload by occlusion with snares. In animals
randomized to ET-1 receptor blockade (ERB group), the standard
cardioplegic solution was supplemented with 100 mol/L of the
mixed endothelin A (ETA) and endothelin B (ETB) receptor an-
tagonist bosentan (Actelion Ltd).
Harvesting Donor Blood for Subsequent Perfusion
During Organ Preservation
The method of delivery and final composition of donor shed blood
perfusate has been described previously.9 In brief, the perfusate
was delivered antegradely through the aortic root intermittently
(200 mL every 20 minutes) at a pressure of 60 mm Hg by means
of gravity throughout the 6-hour storage period. The temperature
was allowed to drift to room temperature (approximately 21°C 
1°C). In the ERB group 100 mol/L bosentan was added to the
perfusate.
Recipient Procedure
Orthotopic implantation of the donor heart to the recipient pro-
ceeded as described previously.9 Bosentan was not added to the
cardioplegic solution once cardiopulmonary bypass (CPB) was
established and was only administered in the ERB group during
harvest and ex vivo perfusion. After completion of all anastomo-
ses, the aortic crossclamp was removed, and all hearts were reper-
fused for a period of 60 minutes. Weaning from CPB was deemed
successful if the animal maintained a mean systemic pressure of 65
mm Hg for 30 minutes. The animal was then killed during anes-
thesia by intravenous potassium chloride injection and exsangui-
nation.
Measurement of Myocardial Metabolic Recovery
Myocardial metabolic recovery was assessed by obtaining simul-
taneous arterial and coronary sinus blood samples, as well as
full-thickness left ventricular (LV) myocardial biopsy specimens.
Blood samples were analyzed for lactate, oxygen, acid, and hemo-
globin content, as described previously.9 Samples were obtained at
baseline, before donor organ arrest, and at the end of organ storage.
In addition, samples were obtained during each cardioplegic dose
at the recipient operation and at 15-minute intervals during the
reperfusion period.
ET-1 and Inflammatory Cytokine Expression
LV tissue was homogenized on ice with Tris-buffered saline (TBS;
10 mmol/L Tris and 100 mmol/L NaCl, pH 7.5) containing 1%
Triton X-100 and protease inhibitors (0.5 g/mL each of aprotinin,
pepstatin, and leupeptin and 0.05 mmol/L phenylmethylsulfonyl
fluoride). The extract was diluted with TBS and assayed in dupli-
cate with an ET-1 ELISA kit (Biomedica). The protein concentra-
tion was determined by using the Bio-Rad DC Dye.
Tumor necrosis factor  (TNF-) and transforming growth
factor  (TGF-) levels were determined by Western immunoblot-
ting. The LV tissue was homogenized on ice with TBS containing
1% Triton X-100 and protease inhibitors (as above). The protein
concentration was determined by using the Bio-Rad DC Dye.
Extracts were subjected to sodium dodecylsulfate–polyacrylamide
gel electrophoresis. Nonreducing conditions were used for TGF-.
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brane and probed with polyclonal primary antibodies (Sigma). The
bands were detected by means of chemiluminescence (Amersham
Biosciences), scanned, and quantified by means of densitometry
(Quantity One, Bio-Rad).
Measures of Oxidant Stress
Total 8-isoprostane (free and esterified) levels were assessed as a
marker of oxidant injury10 by using an EIA kit (Cayman Chemical
Co). The sample preparation protocol outlined in the kit was used
with some modification. In brief, LV tissue was homogenized on
ice in 10 mmol/L phosphate buffer, pH 7.4, containing 0.005%
butylated hydroxy toluene at a ratio of 10 L of buffer per
milligram of tissue. An equal volume of 15% KOH was added to
the whole homogenate and incubated at 40°C for 60 minutes. The
sample was centrifuged, and the supernatant was neutralized with
1 mol/L KH2PO4. One milliliter of eicosanoid affinity column
buffer (0.1 mol/L potassium phosphate, pH 7.4, containing 0.5
mol/L NaCl) was added to the sample, which was then purified by
using an 8-isoprostane affinity column, according to the manufac-
turer’s instructions. The samples were assayed at 2 dilutions, in
duplicate, with the EIA kit and read at an absorbance of 405 nm.
Assessment of Ventricular Function
A Millar (Millar Instruments, Inc) high-fidelity micromanometer
catheter (for pressure measurements) and a 5F NUMED conduc-
tance catheter (for volume measurements) were introduced se-
quentially into the left ventricle through an apical ventriculotomy.
The outputs from the micromanometer and conductance catheter
were linked to an analog digital converter and then transferred to
a laptop computer for construction of pressure-volume loops.
Measurements were obtained by using the methods of Baan and
colleagues,11 and parallel conductance was corrected by using the
method of Szwarc and coworkers.12 Once baseline pressure-vol-
ume loops were constructed, the venae cavae were snared for a
minimum of 6 cardiac cycles to allow for the recording of pres-
sure-volume loops at varying preloads. End-systolic elastance was
calculated as the slope and position of the end-systolic point of the
pressure-volume loops. We have found this to be a more sensitive
measure of contractility compared with maximal systolic elas-
tance.13 Preload recruitable stroke work (PRSW) was evaluated by
calculating the relationship between stroke work (area within the
pressure-volume loop) and the end-diastolic volume determined by
our conductance catheter. The linear relationship between stroke
work and end-diastolic volume provides a load-insensitive index
of cardiac function (PRSW).14,15
Assessment of Endothelial Function
Endothelium-dependent and endothelium-independent vascular re-
laxation was assessed in vitro by constructing concentration-re-
sponse curves with a small-vessel myograft for isometric tension
recording. Our preliminary investigations determined that endo-
thelial function was similar immediately after cardiac transplanta-
tion compared with that of normal freshly isolated control arterial
segments (without storage and cardiac transplantation). Jeanmart
and colleagues16 previously determined that 48 hours of cold
storage does not itself induce endothelial dysfunction in normal
porcine epicardial coronary segments but can be used to study the
The Journal of Thoracieffects of late reperfusion. Accordingly, to expose the progressive
endothelial dysfunction that occurs after transplantation, we stored
our vascular segments for 48 hours at 4°C after transplantation.
Normal freshly isolated control arterial segments were performed
on coronary segments obtained from the recipient’s native heart,
which was harvested after cardioplegic arrest and stored similarly
for 48 hours.
In brief, the left anterior descending coronary artery was
cleaned of fat and connective tissue and placed into Krebs-Hense-
leit solution (118.0 mmol/L NaCl, 4.6 mmol/L KCl, 1.2 mmol/L
MgSO4, 2.5 mmol/L CaCl2, 1.2 mmol/L KH2PO4, and 25.0
mmol/L NaHCO3). The tissue was stored at 4°C for 48 hours.
Vessels were cut into 5.0-mm segments and placed into a 25-mL
organ chamber. The rings were suspended between 2 wires, one of
which was connected to an isometric force transducer. Data were
collected with AcqKnowledge software (Biopac Systems Inc). The
rings were bathed at all times with Krebs solution containing 11.0
mmol/L glucose at 37°C and oxygenated with a 95% oxygen/5%
carbon dioxide mixture. The tissue was stretched to 3 g and
allowed to stabilize for 90 minutes. The rings were contracted with
100 mmol/L KCl and, after washout, stabilized once again for 30
minutes.
The tissue rings were precontracted with a thromboxane A2
analog, U46619 compound (30 nmol/L). Endothelium-dependent
vasorelaxation was assessed on the basis of a dose response to
bradykinin (0.25 nmol/L to 1.0 mol/L), and similarly, endothe-
lium-independent vasodilation was assessed on the basis of a dose
response to sodium nitroprusside (10 nmol/L to 5 mol/L). The
percentage of maximum relaxation from preconstriction was com-
pared between groups. Two segments of left anterior descending
coronary artery were obtained from each heart, and the data were
averaged, provided the variability between segments was less than
10%; otherwise, the data was excluded from analysis.
Statistical Analysis
Statistical analysis was performed by the SAS program (Version
8.2 for Windows, SAS Institute). Two-way analysis of variance
was used to compare continuous variables by simultaneously eval-
uating the main effects of time and group. Categorical data were
analyzed by 2 or Fisher exact tests where appropriate.
Analysis of covariance was used to compare the slope of the
stroke work/end-diastolic volume relationship to simultaneously
evaluate the main effects of treatment group and end-diastolic
volume. Exact P values are provided to enable the reader to
determine clinical and statistical significance.
Results
Operative Parameters
There were no differences in the total volume of blood
perfusate harvested from the chest of the donor and subse-
quently perfused during allograft storage. Approximately
3000 mL was harvested in each group. There were no
differences in the total time to initial blood cardioplegic
perfusion before organ implantation (storage time) or in the
total ischemic time because this was carefully controlled by
c and Cardiovascular Surgery ● Volume 129, Number 2 409
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not conform to the study protocol and were eliminated from
Figure 1. ERB supplementation during allograft storage enhances
LV functional recovery after orthotopic transplantation. Despite
the intermittent perfusion of shed donor blood during the period of
ischemic storage, control hearts (ERB-treated hearts) had re-
duced LV function after orthotopic heart transplantation com-
pared with baseline measures. Top, Two independent and load-
insensitive measures of LV performance indicated improved
functional recovery in ERB-treated hearts (ERB) after transplan-
tation (PRSW expressed as percentage of baseline: 88%  6% vs
46%  2%; P  .02). Bottom, The PRSW relationship in cardiac
allografts is shown at baseline (before transplantation) and after
transplantation in control hearts (ERB) and ERB-treated hearts
(ERB). The PRSW relationship showed the characteristic down-
ward (reduced slope) and rightward (increased volume-axis in-
tercept) displacement after transplantation compared with base-
line curves, indicating allograft LV contractile dysfunction.15
However, this displacement of the PRSW relationship was atten-
uated in ERB-treated hearts. The values have been normalized as
described by Ryan and colleagues.15 *P < .05.the study and final analysis.
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Despite the intermittent perfusion of shed donor blood dur-
ing the period of ischemic storage, control hearts had re-
duced LV function after orthotopic heart transplantation
compared with baseline measures (Figure 1). Notably, LV
functional recovery was improved in ERB-treated hearts
after transplantation (Figure 1), as assessed on the basis of
PRSW and end-systolic elastance. The PRSW relationship
showed the characteristic downward (reduced slope) and
rightward (increased volume-axis intercept) displacement
after transplantation compared with baseline curves, indi-
cating allograft LV contractile dysfunction.15 However, this
displacement of the PRSW relationship was attenuated in
ERB-treated hearts (Figure 1). In addition, successful wean-
ing from CPB was greater in the ERB-treated hearts (7/8 vs
5/8), although the difference did not reach statistical signif-
icance (P  .23).
Coronary Endothelial Function
In a series of preliminary studies before studying ERB
treatment, we evaluated coronary endothelial function after
a 6-hour period of storage (before transplantation and reper-
fusion) and also immediately after reperfusion after ortho-
topic transplantation. We were unable to demonstrate acute
changes in endothelial function from baseline after pro-
longed storage or immediately after surgical reperfusion
after transplantation (data not shown). However, when ar-
terial segments were harvested and stored for 48 hours,
significant endothelial dysfunction was evident if the hearts
were exposed to prior surgical reperfusion. Despite storage
for 48 hours, endothelial dysfunction was not observed in
segments free of reperfusion after orthotopic transplantation
(preischemic and poststorage specimens), which is consis-
tent with the prior findings of Jeanmart and colleagues.16
Accordingly, to expose the progressive endothelial dysfunc-
tion that occurs after transplantation, we stored our vascular
segments for 48 hours at 4°C after transplantation.
Endothelial dysfunction was apparent in hearts subjected
to prolonged storage and transplantation and then assessed
after an extended period of storage (Figure 2). Notably,
ERB treatment during storage limited the endothelial dys-
function associated with transplantation and surgical reper-
fusion (Figure 2). ERB treatment had no effect on segments
harvested immediately after storage before transplantation
and reperfusion (Figure 2). Endothelium-independent coro-
nary vasoreactivity was not different between groups at any
time, indicating that the improved coronary vasomotor
function was the result of improved endothelial function
after ERB treatment (Figure 2).
ET-1 and Proinflammatory Cytokine Expression
Myocardial ET-1 protein expression was significantly in-
creased with reperfusion after transplantation compared
uary 2005
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duced from baseline during the period of storage, when the
heart was quiescent and metabolism was similarly dimin-
ished (Figure 3). Notably, ET-1 expression was similar
Figure 2. Transplant-associated endothelial dysfunction is lim-
ited by ERB during allograft storage. Coronary vasoreactivity was
assessed by using an ex vivo macrovascular tissue bath appara-
tus. Vasoreactivity in the donor heart was comparable between
groups immediately after cardioplegic arrest at the time of har-
vest (Post-Arrest). Endothelial-dependent vasoreactivity was im-
paired in both groups 48 hours after transplantation, whereas
endothelial-independent vasoreactivity was unchanged, collec-
tively indicating endothelial dysfunction. ERB treatment during
storage limited the late endothelial dysfunction associated with
prolonged allograft storage and transplantation (%Emax to brady-
kinin: 67%  6% vs 45%  2%; P  .001). BK, Bradykinin; SNP,
sodium Nitroprusside. %Emax, Percentage of maximal elastance.
*P < .05.between groups at all time points assessed (Figure 3). Myo-
The Journal of Thoracicardial protein expression of TNF- did not differ with time
but was less in ERB-treated hearts during the storage period
(Figure 3). Expression of TGF- was similar over time (P
.20) and between groups (ERB-treated subjects vs control
Figure 3. ET-1 and proinflammatory cytokine expression. Myocar-
dial samples from the left ventricle were examined for ET-1
protein levels immediately before allograft harvest in the beating
heart (Pre-Arrest), at the end of allograft storage (Storage), and
after transplantation and surgical reperfusion for 60 minutes
(Reperfusion). ET-1 expression was reduced from baseline in the
quiescent heart during storage but increased with reperfusion (36
 8 vs 15  4 fmol/mg, P  .001). ERB treatment during storage
did not influence the expression of myocardial ET-1. Protein
levels of the proinflammatory cytokines TNF- and TGF- were
assessed by means of immunoblotting in myocardial samples
from the left ventricle. The levels of TNF- were reduced in
ERB-treated hearts during allograft storage. *P < .05.subjects: 120  24 vs 121  28 arbitrary units; P  .20).
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Oxidative stress was assessed in myocardial samples by
measuring 8-isoprostane levels.10 8-Isoprostane levels were
assessed immediately after cardioplegic arrest of the donor
heart (ERB-treated subjects vs control subjects: 1.9 0.4 vs
1.9  0.5 pg/mg protein; P  .20) and again after surgical
reperfusion after transplantation (ERB-treated subjects vs
control subjects: 2.4 1.2 vs 1.6  0.6 pg/mg protein; P 
.20). 8-Isoprostane levels were comparable by group (P 
Figure 4. Cardiac metabolism. Myocardial metabolism was as-
sessed by measuring the extraction or production of lactate,
oxygen, and acid by the heart. As expected, cardiac metabolism
was reduced in the quiescent heart after cardioplegic arrest.
Notably, cardiac metabolism was similar between groups,
thereby excluding enhanced metabolic recovery as the underly-
ing mechanism of benefit on myocardial and endothelial function..20) and by time (P  .20), excluding oxidant stress as the
412 The Journal of Thoracic and Cardiovascular Surgery ● Febrmechanism of benefit observed on both myocardial and
endothelial function.
Myocardial Metabolism
Aerobic metabolism was determined by measuring the ex-
traction or production of oxygen, acid, and lactate from the
heart. ERB treatment did not influence the recovery of
aerobic metabolism at any time point during the study
(Figure 4).
Discussion
Improved endothelial and myocardial protection during al-
lograft storage might be necessary to improve the short-term
and long-term outcomes of clinical heart transplantation.
Endothelial dysfunction after transplantation is triggered by
multiple factors, including early events, such as exposure to
cardioplegic arrest, cold ischemia, preservation solutions,
and reperfusion after implantation.16 ET-1 is an inflamma-
tory cytokine that has been implicated in both endothelial
and myocardial dysfunction, perhaps as a result of its di-
verse effects on cell survival, proliferation, and migration,
as well as extracellular matrix homeostasis, cytokine ex-
pression, and intracellular calcium handling.17 The direct
influence of ET-1 signaling in the setting of cardiac allograft
injury during storage is not clear. The physiologic effects of
ET-1 are largely dependent on the relative expression of its
dual receptor subtypes, ETA and ETB, which have disparate
effects on the circulation. Numerous synthetic ET-1 recep-
tor blockers are readily available for clinical use. Bosentan
is a mixed ETA and ETB receptor blocker available for the
treatment of pulmonary hypertension. In this study, using
bosentan, we evaluated the effects of nonselective ET-1
receptor antagonism during cardiac allograft storage on
limiting early endothelial dysfunction and improving myo-
cardial performance after transplantation.
Enhanced Endothelial Protection
The results of our study indicate that ET-1 signaling might
directly contribute to endothelial dysfunction after allograft
preservation and subsequent reperfusion after transplanta-
tion. Allograft coronary endothelial dysfunction was a late
consequence of reperfusion after prolonged storage. How-
ever, it should be noted that animals were killed immedi-
ately after functional assessments made after the surgical
reperfusion period. Thus, we did not assess endothelial
function after prolonged reperfusion in vivo. We stored our
vascular rings ex vivo in a solution for 48 hours to enhance
our ability to detect endothelial dysfunction after transplan-
tation, recognizing that this might not necessarily reflect
changes consistent with in vivo reperfusion.
Importantly, ET-1 receptor blockage during the period of
donor cardioplegic arrest and storage was sufficient to pre-
vent the endothelial dysfunction observed after reperfusion.
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at the time of donor implantation resulted in profound
systemic vasodilatation and instability. Thus, in this study
we assessed the role of targeted ET-1 blockade during
harvest and allograft storage alone. Our results indicate an
extended benefit with targeted ERB administration during
storage while avoiding adverse consequences on systemic
hemodynamics during CPB. We used a high dose of bosen-
tan in this study, and these adverse effects on hemodynam-
ics during CPB could perhaps be attenuated by reducing the
dose of bosentan.
Because early endothelial injury from ET-1 bioactivity in
the heart is believed to mediate the subsequent development
of coronary allograft vasculopathy,3,7 the enhanced endo-
thelial protection we observed might have considerable late
benefits. These will be assessed in future studies.
Enhanced Allograft Functional Recovery
Allograft contractile performance was evaluated by using
load-insensitive measures of LV systolic function from
pressure-volume loop analysis after caval occlusion. ET-1
blockade enhanced the recovery of LV function after trans-
plantation, as assessed on the basis of both PRSW and
end-systolic elastance. Importantly, the PRSW relationship
is a sensitive measure of porcine allograft LV functional
recovery after orthotopic transplantation.15 Transplanted
hearts revealed a characteristic downward and rightward
shift after transplantation, indicating LV contractile dys-
function.15 However, decrease of PRSW was attenuated in
the ERB-treated allografts, indicating beneficial effects on
LV recovery.
Myocardial interstitial ET-1 expression is associated
with ischemic injury in human transplant recipients.7 Be-
cause allograft performance is negatively influenced by
ischemia-reperfusion injury, it follows that this mode of
injury was likely minimized by ET-1 blockade. Interest-
ingly, myocardial metabolism was unchanged by ET-1
blockage, and consequently, the improved recovery of LV
function might not necessarily be related to an altered
metabolic state. Similarly, oxidative stress, as inferred on
the basis of 8-isoprostane levels, was comparable between
groups, suggesting that ET-1–mediated attenuation of free
radical production might not be a primary mechanism of
benefit. However, the techniques used in this study might
not be able to discriminate subtle changes in myocardial
metabolism and free radical injury, and accordingly, we
cannot completely rule out these critical pathways as poten-
tial mediators in the beneficial effects of ERB on allograft
recovery.
It is conceivable that improved endothelial function
could result in enhanced contractile function by improving
myocardial perfusion and a washout of toxic metabolites
that accumulate during storage. We were not able to dem-
The Journal of Thoracionstrate endothelial dysfunction early after transplantation
and reperfusion by using a macrovascular tissue bath appa-
ratus. It is possible that microvascular endothelial dysfunc-
tion was present at the time of LV performance assessment
but could not be measured by our technique. The demon-
stration of significant endothelial dysfunction at a later time
suggests that injury was indeed ongoing and induced by the
period of storage.
Although ET-1 accumulation was not suppressed by
ERB, receptor blockage likely resulted in attenuated ET-1
bioactivity, despite its enhanced expression. However, we
did not specifically measure ET-1 bioactivity. Because ET-1
levels accumulated during storage and were increased at the
time of LV performance assessment, it is possible that
reduced ET-1 bioactivity by the nonselective ERB with
bosentan directly improved myocardial contractility.
Whereas the vasoconstrictor effects of ET-1 are widely
recognized, activation of the ETA receptor has direct effects
on myocyte biology, including contractile protein interac-
tions, inotropic state, protein expression, and electrophysi-
ology.4 Numerous studies indicate that ET-1 has a direct
effect on myocardial contractility.4,5,18,19 Accordingly, the
benefits of ERB on allograft LV functional recovery might
be a direct result of this relationship between the ETA
receptor and cardiomyocyte contractile function. Further-
more, expression of TNF- was reduced in hearts treated
with ET-1 blockade, which might also have provided en-
hanced functional recovery, given that the proinflammatory
cytokine TNF- is known to directly impair myocardial
performance after ischemia-reperfusion.20
Limitations
These data are limited to the acute setting after transplan-
tation, and the vascular rings were not exposed to 48 hours
of in vivo reperfusion. Although we have reason to believe
that combined myocardial and endothelial protection will
provide long-term benefits, these issues remain to be eval-
uated. In addition, our technique for the assessment of
endothelial function is an ex vivo method and is limited to
the epicardial coronary vasculature. Myocardial perfusion
was not measured, and it is conceivable that regional per-
fusion differences could result from enhanced endothelial
function. We have inferred a cause-and-effect relationship
between the use of ERB and the observed benefits on
myocardial and endothelial function, particularly because
we have attempted to eliminate other confounding mecha-
nisms that have been implicated in ET-1 signaling, such as
metabolic effects, inflammatory cytokine pathways, and ox-
idant stress. However, our techniques for determining myo-
cardial metabolism and oxidative stress might be insensitive
to detect subtle changes in these indices. Further confirma-
tion with other techniques of assessment might be appro-
priate before it can be concluded that metabolism and oxi-
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ERB. In addition, our study design does not allow us to
directly conclude that attenuated ET-1 bioactivity was
the one and only mechanism leading to the significant
benefits observed in this study. We also cannot exclude a
sex-related effect because only female swine were used
in this study.
Summary
Using a preclinical porcine model of orthotopic heart trans-
plantation, we determined that ET-1 accumulates during
allograft storage and contributes to early endothelial and
myocardial dysfunction after transplantation. ET-1 block-
ade at the time of allograft harvest and continued during
allograft preservation limited endothelial injury and en-
hanced ventricular recovery after transplantation.
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Discussion
Dr Robert C. Robbins (Stanford, Calif). Were the donor heart
ischemic times similar, the same?
Dr Fedak. The ischemic times between groups were identical.
We maintained a protocol that was carefully controlled to provide
a 6-hour ischemic period. Any transplantation that went longer
than the 6-hour limit was eliminated from the study. We measured
ischemic times during the experiment, but there was really no
difference between the groups because we removed the aortic
crossclamp at 6 hours in every animal.
Dr Robbins. You mentioned nitric oxide in your video cartoon.
I did not see anything about it in your article, or did you not
mention anything about nitric oxide production?
Dr Fedak. We did not study nitric oxide production. We do not
believe that ET-1 blockade with a receptor antagonist will directly
affect nitric oxide production. However, it will restore the balance
of nitric oxide with respect to ET-1 bioactivity, which is the critical
balance influencing endothelial function. Accordingly, although
nitric oxide levels might not be influenced by ET-1 blockade, we
are restoring the balance of nitric oxide relative to ET-1 by
blocking ET-1 receptors. Importantly, this is also the reason that
we suggest a combination of L-arginine to increase nitric oxide in
addition to an ET-1 antagonist to decrease ET-1 activity. It might
be best to maximize the balance of these mediators in both direc-
tions. Therefore, that is why we did not study nitric oxide levels in
this study.
Dr Robbins. I was a little disappointed in your article and in
your presentation. You really did not show us any of the pressure-
volume loops and did not really dwell too much on the functional
data, which in my mind would be kind of the whole point of this.
Can you make some comments on specifics of hemodynamics
other than to say that it was better in the treated group?
Dr Fedak. We performed two measures of LV function, both
PRSW and systolic elastance, which are load-insensitive measures
and, as far as I am aware, probably the best measures we have at
the moment to measure ventricular function. On the basis of these
two measures, we saw very similar data indicating improved
cardiac function in the ET-1 antagonist group. We also observed
more of the hearts weaned successfully from CPB. Some of the
more subjective benefits included less myocardial edema and the
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fore, as far as I am aware, we used the most objective and single
best measures of in vivo myocardial function in this study.
Dr David T. Cooke (Palo Alto, Calif). Very interesting study.
I have a question on your cytokine data. You show a significant
difference in TNF- production, yet there were no statistical
differences in your level of oxidative stress. What do you think is
the cause of your differences in TNF- levels? And to follow up
on that, did you check for evidence of apoptosis or differences in
apoptosis that could possibly cause that? Did you look at other
cytokines, such as MCP-1 or IL-1?
Dr Fedak. Thank you for your question. We did not look at the
other cytokines that you mentioned, but we did look at TGF-. We
did not see a difference in TGF- at any other time points or
between groups. Our measure of TNF- was by means of immu-
noblotting, which might not be as sensitive as other methods. We
did only see it at one significant time point. In terms of the
mechanism as to why TNF- levels were being reduced, I cannot
say from the data that we have. I can only say that perhaps with the
blockade of the ET-1 receptor, it is also an inflammatory cyto-
kine—and there is a lot of crosstalk between these cytokines—I
would take it as a surrogate marker of less inflammation and
perhaps less injury. We did not measure cell death, as you men-
tioned, but that would probably be a good thing to do in the future.
Dr Carmelo A. Milano (Durham, NC). I would like to con-
gratulate you on an excellent article. You underplayed perhaps one
of the most important potential contributions of this, and that
would relate to graft vasculopathy. Preservation of the endothe-
lium early on might have very important late effects, and that will
be another important area of study.
The Journal of ThoraciClinically, the time of graft storage is a fairly inert time, and
you did not mention the temperature at which you stored the grafts,
but I was wondering if you were considering administration of this
ET-1 antagonist, perhaps in an experiment in which you treat the
donor during the time of brain death, which is one time when
potential endothelial damage might occur, or treat the graft and the
recipient after reperfusion?
Dr Fedak. Absolutely. Thank you for your points. I did not
stress the allograft vasculopathy because I really have no data to
support it, but that is part of this process, and we do believe that by
protecting the endothelium early, it will have late effects, partic-
ularly on allograft vasculopathy. We have studies ongoing in the
rat heterotopic transplant model to look specifically at that.
In terms of your other point of when to deliver this agent, that
is very important. There is an intravenous form of bosentan,
tezosentan, and it could be given to the brain-dead donor system-
ically before cardioplegic arrest, which I think might have benefits.
In addition, we could give it just as we did in this study quite easily
by adding it into the cardioplegia during the arrest period at the
time of donor organ harvest. Perhaps that alone might have sig-
nificant benefits in the long run without using donor shed blood
perfusion, as we suggest here, which is not done clinically. There-
fore I think there are direct clinical consequences that we could do
quite easily. We would have to study those further, obviously.
As to your second question regarding temperature, in our
patients undergoing cardiac surgery, we try to compromise be-
tween warm and cold heart surgery, and we allow patients to drift
in the operating room, which is what we did for these studies. In
previous studies we found that providing limited coronary perfu-
sion at room temperature led to improved preservation as opposed
to static cold storage.
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